Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Critical Analysis of Neuronal Cell and the Mouse Bioassay for Detection of Botulinum Neurotoxins.

Pellett S, Tepp WH, Johnson EA.

Toxins (Basel). 2019 Dec 7;11(12). pii: E713. doi: 10.3390/toxins11120713. Review.

2.

Botulinum neurotoxins A, B, C, E, and F preferentially enter cultured human motor neurons compared to other cultured human neuronal populations.

Pellett S, Tepp WH, Johnson EA.

FEBS Lett. 2019 Sep;593(18):2675-2685. doi: 10.1002/1873-3468.13508. Epub 2019 Jul 4.

PMID:
31240706
3.

Comparative functional analysis of mice after local injection with botulinum neurotoxin A1, A2, A6, and B1 by catwalk analysis.

Moritz MS, Tepp WH, Inzalaco HN, Johnson EA, Pellett S.

Toxicon. 2019 Sep;167:20-28. doi: 10.1016/j.toxicon.2019.06.004. Epub 2019 Jun 7.

PMID:
31181297
4.

Isolation and Characterization of the Novel Botulinum Neurotoxin A Subtype 6.

Moritz MS, Tepp WH, Bradshaw M, Johnson EA, Pellett S.

mSphere. 2018 Oct 24;3(5). pii: e00466-18. doi: 10.1128/mSphere.00466-18.

5.

The Light Chain Defines the Duration of Action of Botulinum Toxin Serotype A Subtypes.

Pellett S, Bradshaw M, Tepp WH, Pier CL, Whitemarsh RCM, Chen C, Barbieri JT, Johnson EA.

mBio. 2018 Mar 27;9(2). pii: e00089-18. doi: 10.1128/mBio.00089-18.

6.

Enhancing toxin-based vaccines against botulism.

Przedpelski A, Tepp WH, Zuverink M, Johnson EA, Pellet S, Barbieri JT.

Vaccine. 2018 Feb 1;36(6):827-832. doi: 10.1016/j.vaccine.2017.12.064. Epub 2018 Jan 4.

7.

Substrate cleavage and duration of action of botulinum neurotoxin type FA ("H, HA").

Pellett S, Tepp WH, Lin G, Johnson EA.

Toxicon. 2018 Jun 1;147:38-46. doi: 10.1016/j.toxicon.2017.12.048. Epub 2017 Dec 19.

8.

Structural basis for the unique ganglioside and cell membrane recognition mechanism of botulinum neurotoxin DC.

Zhang S, Berntsson RP, Tepp WH, Tao L, Johnson EA, Stenmark P, Dong M.

Nat Commun. 2017 Nov 21;8(1):1637. doi: 10.1038/s41467-017-01534-z.

9.

Small molecule metalloprotease inhibitor with in vitro, ex vivo and in vivo efficacy against botulinum neurotoxin serotype A.

Jacobson AR, Adler M, Silvaggi NR, Allen KN, Smith GM, Fredenburg RA, Stein RL, Park JB, Feng X, Shoemaker CB, Deshpande SS, Goodnough MC, Malizio CJ, Johnson EA, Pellett S, Tepp WH, Tzipori S.

Toxicon. 2017 Oct;137:36-47. doi: 10.1016/j.toxicon.2017.06.016. Epub 2017 Jul 8.

10.

Metal Ions Effectively Ablate the Action of Botulinum Neurotoxin A.

Bremer PT, Pellett S, Carolan JP, Tepp WH, Eubanks LM, Allen KN, Johnson EA, Janda KD.

J Am Chem Soc. 2017 May 31;139(21):7264-7272. doi: 10.1021/jacs.7b01084. Epub 2017 May 19.

11.

Assessment of ELISA as endpoint in neuronal cell-based assay for BoNT detection using hiPSC derived neurons.

Pellett S, Tepp WH, Johnson EA, Sesardic D.

J Pharmacol Toxicol Methods. 2017 Nov;88(Pt 1):1-6. doi: 10.1016/j.vascn.2017.04.013. Epub 2017 Apr 29.

12.

Interneuronal Transfer and Distal Action of Tetanus Toxin and Botulinum Neurotoxins A and D in Central Neurons.

Bomba-Warczak E, Vevea JD, Brittain JM, Figueroa-Bernier A, Tepp WH, Johnson EA, Yeh FL, Chapman ER.

Cell Rep. 2016 Aug 16;16(7):1974-87. doi: 10.1016/j.celrep.2016.06.104. Epub 2016 Aug 4.

13.

Purification and Characterization of Botulinum Neurotoxin FA from a Genetically Modified Clostridium botulinum Strain.

Pellett S, Tepp WH, Bradshaw M, Kalb SR, Dykes JK, Lin G, Nawrocki EM, Pier CL, Barr JR, Maslanka SE, Johnson EA.

mSphere. 2016 Feb 24;1(1). pii: e00100-15. doi: 10.1128/mSphere.00100-15. eCollection 2016 Jan-Feb.

14.

Human Induced Pluripotent Stem Cell Derived Neuronal Cells Cultured on Chemically-Defined Hydrogels for Sensitive In Vitro Detection of Botulinum Neurotoxin.

Pellett S, Schwartz MP, Tepp WH, Josephson R, Scherf JM, Pier CL, Thomson JA, Murphy WL, Johnson EA.

Sci Rep. 2015 Sep 28;5:14566. doi: 10.1038/srep14566.

15.

Heat-Labile Enterotoxin IIa, a Platform To Deliver Heterologous Proteins into Neurons.

Chen C, Przedpelski A, Tepp WH, Pellett S, Johnson EA, Barbieri JT.

mBio. 2015 Aug 11;6(4):e00734. doi: 10.1128/mBio.00734-15.

16.

Botulinum Neurotoxins Can Enter Cultured Neurons Independent of Synaptic Vesicle Recycling.

Pellett S, Tepp WH, Scherf JM, Johnson EA.

PLoS One. 2015 Jul 24;10(7):e0133737. doi: 10.1371/journal.pone.0133737. eCollection 2015.

17.

In vivo onset and duration of action varies for botulinum neurotoxin A subtypes 1-5.

Pellett S, Tepp WH, Whitemarsh RC, Bradshaw M, Johnson EA.

Toxicon. 2015 Dec 1;107(Pt A):37-42. doi: 10.1016/j.toxicon.2015.06.021. Epub 2015 Jun 27.

18.

A Novel Botulinum Neurotoxin, Previously Reported as Serotype H, Has a Hybrid-Like Structure With Regions of Similarity to the Structures of Serotypes A and F and Is Neutralized With Serotype A Antitoxin.

Maslanka SE, Lúquez C, Dykes JK, Tepp WH, Pier CL, Pellett S, Raphael BH, Kalb SR, Barr JR, Rao A, Johnson EA.

J Infect Dis. 2016 Feb 1;213(3):379-85. doi: 10.1093/infdis/jiv327. Epub 2015 Jun 10.

19.

Activity of botulinum neurotoxin type D (strain 1873) in human neurons.

Pellett S, Tepp WH, Scherf JM, Pier CL, Johnson EA.

Toxicon. 2015 Jul;101:63-9. doi: 10.1016/j.toxicon.2015.04.015. Epub 2015 Apr 30.

20.

Immunoprecipitation of native botulinum neurotoxin complexes from Clostridium botulinum subtype A strains.

Lin G, Tepp WH, Bradshaw M, Fredrick CM, Johnson EA.

Appl Environ Microbiol. 2015 Jan;81(2):481-91. doi: 10.1128/AEM.02817-14. Epub 2014 Oct 31.

21.

Analysis of gene expression in induced pluripotent stem cell-derived human neurons exposed to botulinum neurotoxin A subtype 1 and a type A atoxic derivative.

Scherf JM, Hu XS, Tepp WH, Ichtchenko K, Johnson EA, Pellett S.

PLoS One. 2014 Oct 22;9(10):e111238. doi: 10.1371/journal.pone.0111238. eCollection 2014.

22.

Holotoxin Activity of Botulinum Neurotoxin Subtype A4 Originating from a Nontoxigenic Clostridium botulinum Expression System.

Bradshaw M, Tepp WH, Whitemarsh RC, Pellett S, Johnson EA.

Appl Environ Microbiol. 2014 Dec;80(23):7415-22. doi: 10.1128/AEM.01795-14. Epub 2014 Sep 19.

23.

Multiple domains of tetanus toxin direct entry into primary neurons.

Blum FC, Tepp WH, Johnson EA, Barbieri JT.

Traffic. 2014 Oct;15(10):1057-65. doi: 10.1111/tra.12197. Epub 2014 Aug 11.

24.

Widespread sequence variations in VAMP1 across vertebrates suggest a potential selective pressure from botulinum neurotoxins.

Peng L, Adler M, Demogines A, Borrell A, Liu H, Tao L, Tepp WH, Zhang SC, Johnson EA, Sawyer SL, Dong M.

PLoS Pathog. 2014 Jul 10;10(7):e1004177. doi: 10.1371/journal.ppat.1004177. eCollection 2014 Jul.

25.

Persistence of botulinum neurotoxin a subtypes 1-5 in primary rat spinal cord cells.

Whitemarsh RC, Tepp WH, Johnson EA, Pellett S.

PLoS One. 2014 Feb 27;9(2):e90252. doi: 10.1371/journal.pone.0090252. eCollection 2014.

26.

Entry of a recombinant, full-length, atoxic tetanus neurotoxin into Neuro-2a cells.

Blum FC, Przedpelski A, Tepp WH, Johnson EA, Barbieri JT.

Infect Immun. 2014 Feb;82(2):873-81. doi: 10.1128/IAI.01539-13. Epub 2013 Dec 9.

27.

Targeting botulinum A cellular toxicity: a prodrug approach.

Silhár P, Eubanks LM, Seki H, Pellett S, Javor S, Tepp WH, Johnson EA, Janda KD.

J Med Chem. 2013 Oct 24;56(20):7870-9. doi: 10.1021/jm400873n. Epub 2013 Oct 15.

28.

Comparison of the catalytic properties of the botulinum neurotoxin subtypes A1 and A5.

Wang D, Krilich J, Pellett S, Baudys J, Tepp WH, Barr JR, Johnson EA, Kalb SR.

Biochim Biophys Acta. 2013 Dec;1834(12):2722-8. doi: 10.1016/j.bbapap.2013.09.007. Epub 2013 Oct 2.

29.

Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro.

Whitemarsh RC, Tepp WH, Bradshaw M, Lin G, Pier CL, Scherf JM, Johnson EA, Pellett S.

Infect Immun. 2013 Oct;81(10):3894-902. doi: 10.1128/IAI.00536-13. Epub 2013 Aug 5.

30.

Enhancing the protective immune response against botulism.

Przedpelski A, Tepp WH, Kroken AR, Fu Z, Kim JJ, Johnson EA, Barbieri JT.

Infect Immun. 2013 Jul;81(7):2638-44. doi: 10.1128/IAI.00382-13. Epub 2013 May 13.

31.

A microscale neuron and Schwann cell coculture model for increasing detection sensitivity of botulinum neurotoxin type A.

Hong WS, Young EW, Tepp WH, Johnson EA, Beebe DJ.

Toxicol Sci. 2013 Jul;134(1):64-72. doi: 10.1093/toxsci/kft082. Epub 2013 Apr 5.

PMID:
23564642
32.

Association of toxin-producing Clostridium botulinum with the macroalga Cladophora in the Great Lakes.

Chun CL, Ochsner U, Byappanahalli MN, Whitman RL, Tepp WH, Lin G, Johnson EA, Peller J, Sadowsky MJ.

Environ Sci Technol. 2013 Mar 19;47(6):2587-94. doi: 10.1021/es304743m. Epub 2013 Mar 4.

PMID:
23421373
33.

Cytotoxicity of botulinum neurotoxins reveals a direct role of syntaxin 1 and SNAP-25 in neuron survival.

Peng L, Liu H, Ruan H, Tepp WH, Stoothoff WH, Brown RH, Johnson EA, Yao WD, Zhang SC, Dong M.

Nat Commun. 2013;4:1472. doi: 10.1038/ncomms2462.

34.

Model for studying Clostridium botulinum neurotoxin using differentiated motor neuron-like NG108-15 cells.

Whitemarsh RC, Pier CL, Tepp WH, Pellett S, Johnson EA.

Biochem Biophys Res Commun. 2012 Oct 19;427(2):426-30. doi: 10.1016/j.bbrc.2012.09.082. Epub 2012 Sep 20.

35.

Botulinum neurotoxins B and E translocate at different rates and exhibit divergent responses to GT1b and low pH.

Sun S, Tepp WH, Johnson EA, Chapman ER.

Biochemistry. 2012 Jul 17;51(28):5655-62. Epub 2012 Jul 2.

36.

Botulinum neurotoxin D-C uses synaptotagmin I and II as receptors, and human synaptotagmin II is not an effective receptor for type B, D-C and G toxins.

Peng L, Berntsson RP, Tepp WH, Pitkin RM, Johnson EA, Stenmark P, Dong M.

J Cell Sci. 2012 Jul 1;125(Pt 13):3233-42. doi: 10.1242/jcs.103564. Epub 2012 Mar 27.

37.

Purification and characterization of a novel subtype a3 botulinum neurotoxin.

Tepp WH, Lin G, Johnson EA.

Appl Environ Microbiol. 2012 May;78(9):3108-13. doi: 10.1128/AEM.07967-11. Epub 2012 Feb 24.

38.

Novel application of human neurons derived from induced pluripotent stem cells for highly sensitive botulinum neurotoxin detection.

Whitemarsh RC, Strathman MJ, Chase LG, Stankewicz C, Tepp WH, Johnson EA, Pellett S.

Toxicol Sci. 2012 Apr;126(2):426-35. doi: 10.1093/toxsci/kfr354. Epub 2012 Jan 5.

39.

Retargeted clostridial neurotoxins as novel agents for treating chronic diseases.

Yeh FL, Zhu Y, Tepp WH, Johnson EA, Bertics PJ, Chapman ER.

Biochemistry. 2011 Dec 6;50(48):10419-21. doi: 10.1021/bi201490t. Epub 2011 Nov 7.

40.

Receptor binding enables botulinum neurotoxin B to sense low pH for translocation channel assembly.

Sun S, Suresh S, Liu H, Tepp WH, Johnson EA, Edwardson JM, Chapman ER.

Cell Host Microbe. 2011 Sep 15;10(3):237-47. doi: 10.1016/j.chom.2011.06.012.

41.

Subunit vaccine efficacy against Botulinum neurotoxin subtypes.

Henkel JS, Tepp WH, Przedpelski A, Fritz RB, Johnson EA, Barbieri JT.

Vaccine. 2011 Oct 13;29(44):7688-95. doi: 10.1016/j.vaccine.2011.07.134. Epub 2011 Aug 10.

42.

Rapid immune responses to a botulinum neurotoxin Hc subunit vaccine through in vivo targeting to antigen-presenting cells.

White DM, Pellett S, Jensen MA, Tepp WH, Johnson EA, Arnason BG.

Infect Immun. 2011 Aug;79(8):3388-96. doi: 10.1128/IAI.00166-11. Epub 2011 May 16.

43.

Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors.

Peng L, Tepp WH, Johnson EA, Dong M.

PLoS Pathog. 2011 Mar;7(3):e1002008. doi: 10.1371/journal.ppat.1002008. Epub 2011 Mar 31.

44.

Neuronal targeting, internalization, and biological activity of a recombinant atoxic derivative of botulinum neurotoxin A.

Pellett S, Tepp WH, Stanker LH, Band PA, Johnson EA, Ichtchenko K.

Biochem Biophys Res Commun. 2011 Feb 25;405(4):673-7. doi: 10.1016/j.bbrc.2011.01.093. Epub 2011 Feb 1.

45.

Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin.

Garcia-Rodriguez C, Geren IN, Lou J, Conrad F, Forsyth C, Wen W, Chakraborti S, Zao H, Manzanarez G, Smith TJ, Brown J, Tepp WH, Liu N, Wijesuriya S, Tomic MT, Johnson EA, Smith LA, Marks JD.

Protein Eng Des Sel. 2011 Mar;24(3):321-31. doi: 10.1093/protein/gzq111. Epub 2010 Dec 13.

46.

Sensitive and quantitative detection of botulinum neurotoxin in neurons derived from mouse embryonic stem cells.

Pellett S, Du ZW, Pier CL, Tepp WH, Zhang SC, Johnson EA.

Biochem Biophys Res Commun. 2011 Jan 7;404(1):388-92. doi: 10.1016/j.bbrc.2010.11.128. Epub 2010 Dec 3.

47.

Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1.

Pier CL, Chen C, Tepp WH, Lin G, Janda KD, Barbieri JT, Pellett S, Johnson EA.

FEBS Lett. 2011 Jan 3;585(1):199-206. doi: 10.1016/j.febslet.2010.11.045. Epub 2010 Nov 30.

48.

SV2 mediates entry of tetanus neurotoxin into central neurons.

Yeh FL, Dong M, Yao J, Tepp WH, Lin G, Johnson EA, Chapman ER.

PLoS Pathog. 2010 Nov 24;6(11):e1001207. doi: 10.1371/journal.ppat.1001207.

49.

Comparison of the primary rat spinal cord cell (RSC) assay and the mouse bioassay for botulinum neurotoxin type A potency determination.

Pellett S, Tepp WH, Toth SI, Johnson EA.

J Pharmacol Toxicol Methods. 2010 May-Jun;61(3):304-10. doi: 10.1016/j.vascn.2010.01.003. Epub 2010 Jan 25.

PMID:
20100585
50.

Toosendanin: synthesis of the AB-ring and investigations of its anti-botulinum properties (Part II).

Nakai Y, Pellett S, Tepp WH, Johnson EA, Janda KD.

Bioorg Med Chem. 2010 Feb;18(3):1280-7. doi: 10.1016/j.bmc.2009.12.030. Epub 2009 Dec 22. Erratum in: Bioorg Med Chem. 2011 Jul 1;19(13):4154.

Supplemental Content

Support Center